Axsome Therapeutics (AXSM) News Today → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free AXSM Stock Alerts $73.59 -0.09 (-0.12%) (As of 12:26 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAxsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q2 2024 Earnings of ($1.31) Per Share, HC Wainwright Forecastsmarketbeat.com - May 10 at 7:55 AMWhy Axsome Therapeutics Is A Promising Stock Pick In CNS Treatmentsseekingalpha.com - May 10 at 6:31 AMAxsome Therapeutics (NASDAQ:AXSM) PT Lowered to $106.00americanbankingnews.com - May 10 at 4:36 AMHC Wainwright Weighs in on Axsome Therapeutics, Inc.'s Q3 2025 Earnings (NASDAQ:AXSM)americanbankingnews.com - May 10 at 4:02 AMAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of "Moderate Buy" from Analystsamericanbankingnews.com - May 10 at 3:12 AMQ2 2024 Earnings Forecast for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Issued By William Blairamericanbankingnews.com - May 10 at 2:18 AMAxsome Therapeutics, Inc. to Post Q2 2024 Earnings of ($1.46) Per Share, Leerink Partnrs Forecasts (NASDAQ:AXSM)americanbankingnews.com - May 10 at 2:18 AMAxsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Yearfinance.yahoo.com - May 9 at 10:29 AMAxsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q3 2025 Earnings of $0.47 Per Share, HC Wainwright Forecastsmarketbeat.com - May 9 at 7:55 AMLeerink Partnrs Comments on Axsome Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:AXSM)americanbankingnews.com - May 9 at 2:32 AMAxsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $106.00 at Mizuhomarketbeat.com - May 8 at 8:37 AMBuy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical Trialsmarkets.businessinsider.com - May 8 at 7:56 AMFY2026 EPS Estimates for Axsome Therapeutics, Inc. Reduced by Analyst (NASDAQ:AXSM)marketbeat.com - May 8 at 7:36 AMAxsome Therapeutics to Present at Upcoming Investor Conferencesglobenewswire.com - May 8 at 7:00 AMAxsome Therapeutics (NASDAQ:AXSM) Given Buy Rating at HC Wainwrightamericanbankingnews.com - May 8 at 6:08 AMAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $112.00 at Robert W. Bairdamericanbankingnews.com - May 8 at 6:08 AMAxsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $125.00 by Analysts at Citigroupamericanbankingnews.com - May 8 at 6:08 AMAxsome Therapeutics (NASDAQ:AXSM) PT Lowered to $125.00marketbeat.com - May 7 at 2:02 PMBuy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic Positioningmarkets.businessinsider.com - May 7 at 11:55 AMAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - May 7 at 11:55 AMAxsome Therapeutics (NASDAQ:AXSM) Rating Reiterated by HC Wainwrightmarketbeat.com - May 7 at 8:32 AMRobert W. Baird Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $112.00marketbeat.com - May 7 at 8:32 AMBuy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion Potentialmarkets.businessinsider.com - May 7 at 6:54 AMAxsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...finance.yahoo.com - May 7 at 6:54 AMQ1 2024 Axsome Therapeutics Inc Earnings Callfinance.yahoo.com - May 7 at 1:54 AMAxsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcriptfool.com - May 6 at 3:51 PMAXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024investorplace.com - May 6 at 2:41 PMAxsome: Q1 Earnings Snapshotwashingtonpost.com - May 6 at 10:50 AMAxsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15Mmsn.com - May 6 at 10:50 AMAxsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updateglobenewswire.com - May 6 at 7:00 AMInvestors Beware of These 3 Pharma Stocksstocknews.com - May 2 at 5:04 PMCannell & Co. Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - May 2 at 8:40 AMAxsome Therapeutics Recognizes May as Mental Health Awareness Monthglobenewswire.com - May 1 at 7:00 AM3 Biotech Stocks with Blockbuster Drug Pipelines: April Editioninvestorplace.com - April 30 at 3:20 PMAxsome Therapeutics (NASDAQ:AXSM) Upgraded to Overweight by Morgan Stanleyamericanbankingnews.com - April 30 at 5:32 AMGinkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directorsfinance.yahoo.com - April 29 at 5:30 PMAxsome Therapeutics (NASDAQ:AXSM) Shares Gap Up to $71.71marketbeat.com - April 29 at 1:34 PMBuy Rating on Axsome Therapeutics Amidst Strong Auvelity Performance and Positive Revenue Prospectsmarkets.businessinsider.com - April 29 at 12:30 PMAxsome Therapeutics stock rises on upgrade to Overweight at Morgan Stanleymsn.com - April 29 at 12:30 PMPeeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insightsmarkets.businessinsider.com - April 29 at 12:30 PMAxsome Therapeutics (NASDAQ:AXSM) Rating Increased to Overweight at Morgan Stanleymarketbeat.com - April 29 at 7:32 AMBuy Rating Affirmed for Axsome Therapeutics Amidst Anticipated Clinical Data and Resilient Product Performancemarkets.businessinsider.com - April 26 at 11:47 AMBrokers Offer Predictions for Axsome Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:AXSM)marketbeat.com - April 19 at 8:18 AMStrong Buy on Axsome’s Auvelity Amidst Competitive MDD Marketmarkets.businessinsider.com - April 18 at 7:36 AMAuvelity’s Strong Performance Sustains Buy Rating for Axsome Therapeuticsmarkets.businessinsider.com - April 16 at 7:50 AMPhocas Financial Corp. Acquires New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - April 15 at 8:29 AMAxsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meetingglobenewswire.com - April 15 at 7:00 AMLeerink Partnrs Research Analysts Reduce Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - April 11 at 7:58 AMAxsome Therapeutics' (AXSM) Overweight Rating Reaffirmed at Cantor Fitzgeraldmarketbeat.com - April 10 at 10:25 AM2 Under-the-Radar Growth Stocks to Considerfool.com - April 10 at 10:15 AM Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address This 1 Biotech Stock has been shocking the markets (Ad)Save the Date: BioStem's 2024 Q1 Call Coming Up! Sign Up for the Live Broadcast here AXSM Media Mentions By Week AXSM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.220.45▲Average Medical News Sentiment AXSM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼466▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CORT News HRMY News TARO News XNCR News VIR News INVA News TXG News RARE News CRNX News SWTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
